INTRODUCTION
We and others have conducted clinical studies in patients with symptoms of autoimmune liver disease [1] , hepa titis C [2, 3] , bacterial infection [4] , acute liver failure liver [5] , 147 WJSC|www.wjgnet.com
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nonalcoholic fatty liver disease [6] and cirrhosis. We have also conducted translational research that bridges basic research using hematopoietic cells [714] , hepatic stellate cells (HSCs) [1518] , embryonic stem cellderived hepatocytes [1922] , bioartificial livers [2326] , animals [2733] and clinical research in humans.
Thanks to their expected therapeutic efficacy, me senchymal stem cells [34] are currently under clinical evaluation as a cell source for cell therapy in trials of regenerative medicine for a broad spectrum of disea ses. Since adiposederived mesenchymal stem cells (ADSCs) [35, 36] are obtained from the patient's abdomen by liposuction, cell procurement is relatively easy (large numbers of cells can be obtained by minimally invasive treatment). ADSCs can avoid immune rejection if they are autografted [3739] ; however, similarly to other cell sour ces, they are subject to immune rejection if allogeneic or xeno cell transplantation is performed. Mesenchymal stem cells are used for medical treatment worldwide. Since ADSCs are not a mainstream therapeutic cell, we have been performing clinical studies of treatments using ADSCs. For this reason, cell therapy using ADSCs is now performed in many public and private hospitals worldwide. In this review, we examine the effects of ADSCs in cell therapy for liver diseases, focusing on the proteins secreted by ADSCs. We previously reported that the proteins expressed by human ADSCs cultured using Dulbecco's Modified Eagle's medium [10% fetal bovine serum (FBS)] and clinicalgrade chemicallydefined medium showed 98% similarity, demonstrating that the proteins expressed by ADSCs cultured in media for research and clinical use largely coincide [40, 41] . However, using animalderived components in the process of culturing cells for treatment is associated with a risk of transmitting pathogenic infections derived from animals (e.g., bovine spongiform encephalopathy or swine fever). Furthermore, when animalderived ingredients are used the risks and quality may vary in individual lots. Thus, the use of chemically defined media with recombinant protein is recommended for largescale culture conditions, such as the manufacturing of therapeutic cells for industrial use. In this background, we use the medium containing FBS as the control medium for the cultivation of research cells, while chemicallydefined media is the first choice for culturing therapeutic cells. In addition, we do not deny the option of using a supplement that uses infectious and highly safe virustested human serum as a raw material for culturing therapeutic cells.
Gene ontology (GO) facilitates [42, 43] the development of a common vocabulary to describe biological conce pts. Terms defined in GO are called GO terms (GO is a classification of biological phenomena that associ ates genes with their known [reported in the existing literature] biological role structured based on given criteria), which are divided into three categories: Bio logical processes, cellular components, and molecular functions. The Gene Ontology Consortium (http://www. WJSC|www.wjgnet.com geneontology.org/) is a database of functional infor mation that aims to describe biological phenomena in standardized terms. In recent years, liquid chroma tography with tandem mass spectrometry (LCMS/ MS) has been used to perform a GO classification of comprehensive expression data using protein analysis software programs. Both a comprehensive expression analysis of proteins using LCMS/MS and a protein GO analysis were performed according to methods that we reported previously [40, 41, 44] . In normal liver tissue, blood flows from the portal vein through the central veins, each of which supplies sufficient blood to the hepatocytes of a single hepatic lobule ( Figure 1) . The blood supply to hepatocytes rema ins sufficient in carbon tetrachloride (CCL4: 0.5 mL/kg) administered acute liver failure model in mice [40, 41] . Liver failure is a defined as a group of diseases associated with the development of symptoms such as jaundice, ascites, hepatic encephalopathy, bleeding tendency, or the like, due to a decrease in the number of hepatocytes or a decrease in their function. Acute liver failure is defined by the presence of necrosis and inflammation in normal liver tissue, with the period until the onset of sympt oms of hepatic insufficiency being within 8 wk. Cases in which the onset of symptoms is 824 wk or > 24 wk are classified as delayed liver failure (late onset hepatic failure; LOHF) and chronic liver failure, respectively. The American Association for the Study of Liver Diseases published a position paper on acute liver failure in 2005 to unify the terms and disease concepts [45] . In contrast to this acute model, the preparation of the CCL4 (2.0 mL/kg)administered cirrhosis model mouse requires more than 6 wk. The liver tissue in this mouse model of liver cirrhosis shows a marked increase in the fiber component of the fibrous septa. This results in the separation of some lobules by fiber components, and the creation of pseudolobules. At the same time, the blood supply to the lobules decreases and liver cell necrosis occurs (Figure 2 ). Chronic liver in jury also results in the differentiation of astrocytes into myofibroblastoid cells, in turn causing the pathogenesis of fibrotic liver injury [46] . Given this background, the factor most necessary for the improvement of acute liver failure symptoms is hepatocyte growth factor (HGF). In contrast, the most important factors for the impro vement of the symptoms of chronic liver failure (i.e., liver cirrhosis) are: (1) growth factors; (2) inhibition of the inflammation of hepatic stellate cells; and (3) an giogenic factors.
When the disordered repair process is delayed or inhibited after liver damage from drugs, trauma, inflammation, or other insults, liver regeneration is insufficient and hepatic failure develops. In hepatic tissue repair, in addition to growth factors that promote hepatocyte proliferation, angiogenic factors that pro mote hepatic microvascular remodeling are important. In addition, the extracellular matrix in the liver is mainly produced in hepatic stellate cells. The ability of hepatic stellate cells to produce extracellular matrix is low in the normal liver. However, in the fibrous liver, it is known that hepatic stellate cells are activated to differentiate into myofibroblasts and their ability to produce extrace llular matrix markedly increases. Interleukin6 (IL6), tumor necrosis factorα, HGF, and other factors secre ted from HSCs, hepatic sinusoidal endothelial cells and Kupffer cells are thought to have the greatest influ ence on hepatocyte proliferation [47] . Angiogenesis is a physiological phenomenon in which a new blood vessel branch is branched from an existing blood vessel to cons truct a vascular network. The various factors involved in angiogenesis include fibroblast growth factor, vascular endothelial cell growth factor (VEGF), angiopoietin, and platelet derived growth factor (PDGF).
GROWTH FACTORS IMPROVING THE

SYMPTOMS OF LIVER CIRRHOSIS
HGF acts as a HGF and metabolic regulator and promo tes hepatocyte proliferation [48] . The hepatic development of the liver is the origin of the gut tube, which is formed by the accumulation of hematopoietic cells [49] . Thus, the idea that HGF expressed by hematopoietic cells promotes the regeneration of hepatocytes is plausible. Liver tissue regeneration using HGF may accordingly be considered a treatment method that reproduces the original development of the liver. HGF is expressed by both HSCs and ADSCs.
Our group previously investigated the clinical app lication of organ preservation solution [5056] . We found that the expression level of HGF mRNA did not decrease in ADSCs, even when they were stored in preservation solution for 16 h after separation from adipose tissue. In addition, we found no difference between the expression levels of HGF using glucosefree University of Wisconsin and glucosecontaining (5.6 mmol/L) Hank's Balanced Salt Solution. This result shows that the expression of HGF by ADSCs does not decrease after separation from adipose tissue. Moreover, the expression is not affected by the glucose concentration. In addition, the expression of VEGF showed a similar tendency. In short, ADSCs constantly express HGF and VEGF both in vivo and in vitro [57] . A recent theory suggests that the biliary tree functions as a source of liver and pancreatic stem cells and progenitor cells. VEGF is secreted by the biliary tree as a response to stress [58] . From these developmental perspectives, HGF and VEGF secreted by ADSCs app ear to have a marked promoting effect on hepatocyte proliferation.
Our experiments showed that the administration of ADSC conditioned medium (CM) from a single vein rapidly promotes the cellular proliferation of mouse he patocytes ( Figure 3 ). The proteins associated with a growth function (GO analysis), identified by the presen 149 WJSC|www.wjgnet.com In healthy liver tissue, adjacent lobules are separated by thin fibrous septa. However, liver cirrhosis involves thickening of the fibrous septa that separate lobules, and the deposition of fat. As a result, the blood flow in the lobules is disturbed and hepatocyte necrosis occurs. Also, the fibrous septa that separate the lobules transform the lobules and produce pseudolobules. Although it has a wide variety of causes, liver cirrhosis is most commonly caused by chronic alcohol abuse, chronic hepatitis, and nonalcoholic fatty liver disease. Images were obtained from BIODIGITAL HUMAN 3.0 (https://human.biodigital.com/index.html) (BioDigital, Broadway, NY, United States).
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November 26, 2018|Volume 10|Issue 11| 151 WJSC|www.wjgnet.com ce of ADSCCM, were Periostin (POSTN), P component (SAP), semaphorin 7A (SEM7A), and Inactive tyrosine protein kinase 7 [40, 41] . Periostin, which is encoded by the POSTIN gene, has been reported to be an extracellular factor that promotes hepatosteatosis [59, 60] . Nevertheless, much remains unknown about proteins with the ability to promote the cellular proliferation of hepatocytes. For example, SAP, a protein that is expressed in hepatocy tes and secreted into serum, is known to be involved in processes associated with immune regulation, such as the action of opsonins [61] , but whether SAP is invo lved in the cellular proliferation of hepatocytes is unknown. Further, SEM7A is known to contribute to transforming growth factor (TGF)βmediated hepatic fibrosis [62] , but whether it promotes hepatocyte cell pro liferation is unknown. Future studies should therefore investigate whether the growthassociated proteins that are newly identified by GO analyses promote the cellular proliferation of hepatocytes in CCL4induced liver impairment. What is certain is that HGF and VEGF secreted by ADSCs are among the key factors promoting the proliferation of hepatocytes.
INFLAMMATION INHIBITOR OF HEPATIC STELLATE CELLS
The Jun aminoterminal kinases (JNK) signaling pathway is involved in the activation of HSCs [63, 64] . JNK1 plays a major role in the upregulation of the αSMA expression in HSCs under the stress conditions induced by TGFβ during liver fibrosis [65] . We previously reported the clinical application of organ preservation solution with a JNK inhibitory peptide (11RJNKI) [6668] and 8RsJNKI(9) [69] . The design of these cellpermeable inhibitory peptides is not only significant for in vivo studies, but also for future attempts to design inhibitors of liver fibrosis for the clinical treatment of liver cirrhosis. In addition, we previously reported that ArgGlyAsp (RGD) peptide [70] and Rhokinase inhibitor [71] suppresses liver fibrosis. Our bability of causing the death of the mouse. Our group developed a method to safely administer ADSCs using heparin [72] . The proteins associated with the immune system process (GO analysis) identified by the presence of ADSCCM were FINC, CO1A2, CO1A1, CATB, TSP1, CFAH, GAS6, LEG1, PTX3, C1S, SEM7A, CLUS, G3P, PXDN, SRCRL, CD248, SPON2, ENPP2, CD109, CFAB, CATL1, MFAP5, MIF, CXCL5, ADA M9, and CATK (Table 1 ) [40, 41] . Among these ADSCsecreted proteins, we found no studies reporting a relationship in the field of liver cirrhosis and hepatic stellate cells for FINC, CO1A2, CATB, CFAH, LEG1, C1S, SEM7A, CLUS, G3P, PXDN, SRCRL, SPON2, ENPP2, CD109, CFAB, CATL1, MFAP5, ADAM9, or CATK. It is expected that these proteins will be investigated in future studies. Type I collagen and fibronectin are also reported to be components of hepatic fibrosis [73, 74] . It is therefore unlikely that CO1A1 and CO1A2, which are secreted by ADSCs, suppress the excess activity of HSCs. Thrombospondin1, a matricellular glycoprotein that is secreted by many cell types, modulates a variety of cellular functions by binding to extracellular proteins and/or cell surface receptors. Thrombospondin1 might contribute to liver fibrosis not only as an activator of TGFβ, but also as a modulator of angiogenesis [75] . [76] . Given that Gas6 and Axl are reported to be necessary for HSC activation [77] , Gas6 secreted by ADSCs seems to have no effect in inhibiting the activity of HSCs. Pentraxin 3 (PTX3) is expressed and released by hematopoietic cells and stromal cells and is an essential component of innate immunity. IL1 induces the production of PTX3 by Kupffer cells, endothelial cells and biliary duct epithelial cells. PTX3 is reported to be a biomarker of liver fibrosis in response to hepatic injury [78] . These reports indicate that PTX3 secreted by ADSCs is unlikely to suppress the activation of HSCs. CD248 (endosialin) is a stromal cell marker expressed on fibroblasts and pericytes. During liver injury, myofibroblasts are the main source of fibrotic matrix. Liver fibrosis was reported to be suppressed in CD248 knockout mice [79] , suggesting that it is unlikely that CD248 secreted by ADSCs inhibits hepatic fibrosis. Macrophage migration inhibitory factor (MIF) is a pleiotropic inflammatory cytokine that has been implicated in various inflammatory diseases. MIF knockout mice were reported to have strongly increased fibrosis in a mouse model of chronic liver injury model. This phenomenon was accompanied by no change in the infiltration of intrahepatic immune cells. MIF has an anti fibrotic effect on the liver via the MIF receptor (CD74). In addition, recombinant MIF protein has a similar anti fibrotic effect [80] . These results indicate that MIF secre ted by ADSCs is a major component in the suppression of liver fibrosis. CXCL5 is the best known for its function as a neutrophil chemotactic factor and activator, with a molecular structure similar to that of IL8, 4, 5. CXCL5 is released from monocytes, neutrophils, epithelial cells, fibroblasts and smooth muscle during inflammation. Interestingly, CXCL5 has a proliferative effect on rat hepatocytes. The use of a neutralizing antibody of CXCL5 slowed the liver regeneration rate after partial hepatectomy [81] . The plasma CXCL5 levels are low in patients with chronic liver disease, and CXCL5 may be involved in the pathogenesis of chronic liver disea se [82] . These results strongly indicate the possibility that CXCL5 secreted by ADSCs also promotes hepatocyte proliferation. These findings indicated that MIF is one of the components that suppress liver fibrosis among the ADSCsecreted proteins that we identified. In addition, CXCL5 was identified as a component that promotes hepatocyte proliferation. Of course, the function of these proteins has been previously reported. Table 1 shows 26 different proteins classified as immunomodulatory (GO analysis). The 18 proteins indicated by N/A have not been reported in the liver field, and further research into them is anticipated. Note that proteins that were not classified as immunomodulatory (by a GO analysis) may 
ANGIOGENIC FACTORS
EGF, VEGF and HGF, which are expressed by ADSCs, have a strong angiogenic effect on liver tissue [8385] . Table  2 lists eight types of proteins [Plasminogen activator inhibitor 1 (PAI1), follistatinrelated protein 1 (FSTL1), periostin (POSTN), matrix metalloproteinases 2 (MMP2), TSP1, metalloproteinase inhibitor 1 (TIMP1), Fibulins 3 (FBLN3) and Lactadherin (MFGM)] affecting angiogenesis from among 101 types of proteins secreted by ADSCs. PAI1 is a member of a family of proteins that inhibit plas minogen activators [86] . Although the binding of VEGF to vitronectin induces strong angiogenic signaling, this is inhibited by competitive binding to PAI1 [87] . PAI1 secreted from ADSCs is therefore thought to inhibit angiogenesis by VEGF in liver tissue. FSTL1 is a secretory glycoprotein belonging to the follistatin and SPARC family. FSTL1 was reported to be highly expressed in fibrotic human liver tissue and activated HSCs [88] . FSTL1 has the effect of promoting the activity of HSCs. It is therefore unlikely that FSTL1 secreted by ADSCs affects angiogenesis. POSTN, an extracellular matrix (ECM) molecule of the fasciclin family, has roles in vascular cell differentiation and migration [89] . We therefore hypothesize that POSTN secreted by ADSCs may promote angiogenesis of the liver. MMPs are a family of over 24 zincdependent endopeptidases capable of degrading virtually any component of the ECM [90] . MMP2 plays an important role in the preservation of liver vascular homeostasis via its participation in the TGFβ activation process [91] . MMP2 secreted by ADSCsand many other cell typesis therefore considered to be one of the main factors. TSP1 was reported to be increased in HSCs isolated from the liver in a mouse model of CCL4induced cirrhosis. In liver samples of patients with alcohol cirrhosis and non alcoholic steatohepatitisrelated cirrhosis, TSP1 levels were reported to be increased [92] . It is thought that TSP1 expressed in the liver has the effect of promoting liver fibrosis. If so, it would be unlikely that TSP1 secreted by ADSCs promotes liver angiogenesis. TIMP1 is a widely expressed inhibitor of MMPs. Given that the inhibition of TIMP1 promotes angiogenesis by increasing cell moti lity during fibrovascular invasion [93] , TIMP1 secreted by ADSCs may inhibit liver angiogenesis. FBLNs, a versatile family of extracellular matrix proteins, comprise a small family of widely expressed ECM proteins [94] . FBLN3 has been reported to be an angiogenesis antagonist that regulates cell morphology, growth, adhesion and motility [95] . It is therefore unlikely that FBLN3 secreted by ADSCs promotes liver angiogenesis. MFGM inter acts with alphaVbeta3 and alphaVbeta5 integrins and alters both VEGFdependent Akt phosphorylation and neovascularization [96] . MFGM was reported to promote angiogenesis via enhanced PDGFPDGFRβ signaling mediated by crosstalk of the integrin growth factor receptor [97] . Thus, MFGM secreted by ADSCs is considered to be one of the main components promo ting liver angiogenesis. We recently reported that ADSCs strongly express MFGM and that human MFGM protected dopamine neurons in a rat model of Parkinson's disease model [98] . At the present stage, there are no reports on a therapeutic method for the diseasespecific selection of therapeutic cells that reference to the list of protein components expressed by therapeutic stem cells.
Regarding cell therapy using ADSCs, we believe that excellent effects on immune response control by cell adhesion can be expected based on reports in the literature. For treatment with ADSCCM, we used a method to concentrate ADSCCM 20 times using a 10k filter. ADSCCM is a liquid and has the advantage of November 26, 2018|Volume 10|Issue 11| 155 WJSC|www.wjgnet.com being able to pass through both a 0.22μm sterilizing filter and a 0.10μm virus removal filter. We think that lowering the hurdles to cell therapy by taking advantage of the simple adjustment of the solution will contribute to a wide range of medical needs.
These results suggest that VEGF, HGF, EGF, MMP2, POSTN, and MFGM secreted by ADSCs promote hep atic angiogenesis. Among the 101 proteins expressed by ADSCs, we identified three proteins that promote angiogenesis from among eight proteins reported to be involved in angiogenesis. The further development of research into the 93 other proteins is expected.
A study of oneshot stem cell therapy reported the effects of bone marrowderived mesenchymal stem cell treatment in 53 cirrhosis patients [99] . Although study period was sufficient to observe shortterm sympto matic improvement over a period of days to weeks, it has been reported that there is no improvement in symptoms over the longer term (more than a few months). Although this study did not involve the use of ADSCs, it showed that stem cell treatment improves the symptoms of cirrhosis over the short term. However, it shows that oneshot stem cell therapy does not reset the pathological state of cirrhosis through natural healing power leading to recovery. In this paper, we reported that ADSC has three angiogenesisinducing effects, which promoted the proliferation of hepatocytes, which suppressed the fibrosis of the liver tissue. We believe that medical stakeholders and patients will be more likely to challenge clinical studies of ADSCs in the treatment of cirrhosis. However, it is unlikely that ADSCs play a direct role in controlling all of the pathological conditions of cirrhosis in the body. Thus, we are of the opinion that cell therapy using ADSCs and treatment using ADSCCM will be useful as supplementary treatments.
CONCLUSION
The factors necessary for improvement of the sympt oms of chronic liver failure (i.e. , liver cirrhosis) are: (1) growth factors; (2) inhibitors of hepatic stellate cell inflammation; and (3) angiogenic factors. (1) It is certain that ADSCsecreted HGF and VEGF are among the factors that promote the proliferation of hepatocytes. In addition, CXCL5 was identified as a component that promotes hepatocyte proliferation; (2) MIF, which was one of the ADSCsecreted proteins that we identified that suppressed liver fibrosis; and finally (3) ASDCsecreted VEGF, HGF, EGF, MMP2, POSTN and MFGM are factors that promote hepatic angiogenesis. It seems that the therapeutic effect on the symptoms of cirrhosis is based on ADSCsecreted growth factors, antiinflammatory effects on stellate cells, and the antifibrotic and angiogenic effects of ADSCsecreted proteins.
